

# **Molecular Genetics of Blood Groups**

**Jill R. Storry Ph.D.**

**Blood Centre  
University Hospital  
Lund**




**Dept. of Transfusion Medicine  
Lund University**


**Sweden**



# Blood Groups on the RBC



# Blood Groups Are Inherited As The Products of Genes



Karyotype graphic reproduced with permission from Dr. C Cunniff, Univ. Of Arizona

LE  
OK  
LW  
LU  
H

# **RBC Antigens are the Products of Genes**

- **Antigens carried on proteins are encoded directly by the gene, e.g. *RH, KEL, FY***
- **Carbohydrate antigens are under the control of genes that encode glycosyltransferases, e.g. *ABO, P1, H***

# Genetic Mechanisms That Generate Diversity

- **Single nucleotide polymorphism (SNP)**
  - **Silent**
  - **Missense**
  - **Nonsense**
- **Insertions and deletions**
- **Crossover and recombination**
- **Gene conversion**

# Single Nucleotide Polymorphisms

**SNPs occur every 100 to 300 bases**

- **Silent SNPs do not alter the amino acid sequence**
- **Missense SNPs encode a change of one amino acid to another**
- **Nonsense SNPs cause the change of an encoded amino acid to a stop codon (TAA, TAG, TGA)**
- **SNPs in the conserved splice site sequences may cause altered splicing**

**Useful database:**

**<http://www.ncbi.nlm.nih.gov/SNP/index.html>**

# SNP – Missense Mutations

A change of one nucleotide can alter the amino acid encoded

Example: S and s antigens on Glycophorin B

## *GYPB* exon 4

GA	GAA	ATG	GGA	CAA	CTT	GTC	CAT	CGT	TTC	ACT	GTA	CCA	G	S
	E	M	G	Q	L	V	H	R	F	T	V	P		
GA	GAA	ACG	GGA	CAA	CTT	GTC	CAT	CGT	TTC	ACT	GTA	CCA	G	S
	E	T	G	Q	L	V	H	R	F	T	V	P		

# Most Blood Group Antigens Are the Result of SNPs

Common antigen pairs encoded by SNPs:

RH                      C/c, E/e

MNS                    S/s

Kell                    K/k, Kp<sup>a</sup>/Kp<sup>b</sup>, Js<sup>a</sup>/Js<sup>b</sup>

Duffy                   Fy<sup>a</sup>/Fy<sup>b</sup>, (GATA)

Kidd                   Jk<sup>a</sup>/Jk<sup>b</sup>


Lutheran              Lu<sup>a</sup>/Lu<sup>b</sup>

Dombrock            Do<sup>a</sup>/Do<sup>b</sup>

Many other examples of high incidence and low  
incidence antigens

# Genetic Mechanisms That Generate Diversity

- Deletion/addition of nucleotides will alter the open reading frame
  - May result in generation of a premature stop codon e.g. *O* gene




*O1* allele encodes an inactive protein of 117 amino acids

# Genetic Mechanisms That Generate Diversity


Deletion/addition of nucleotides will alter the open reading frame

- May result in a longer open reading frame e.g.  $A^2$  gene



$A^2$  transferase is 375 amino acids long compared with  $A^1$  transferase, which is 354 amino acids in length. The  $A^2$  enzyme is not as active.

# Homology Between Genes Creates Diversity




# Genetic Mechanisms That Generate Diversity

Genes with high sequence identity can misalign during meiosis  
e.g. in the MNS system




Exchange of DNA by unequal crossover

# Different Mechanisms Can Produce The Same Antigen



# Genetic Mechanisms That Generate Diversity

Promoter Mutations Affect RBC Antigen Expression:  
T>C mutation in the *GATA* box prevents transcription of the *FY* gene



§In *Fy*(a–b–) persons of African descent, the *FY* gene encodes *FY*<sup>B</sup>


# **Analysis of Blood Group Polymorphisms**

# Different PCR strategies

- 🔥 PCR with sequence- (or allele-) specific primers (PCR-SSP or PCR-ASP):



- 🔥 PCR followed by restriction endonuclease digestion (PCR-RFLP):



# Possible reasons for ABO genotyping

- **Acquired weakness of A or B antigen expression**
  - ✓ e.g. in leukemia
- **Acquired A or B antigens**
  - ✓ e.g. gastrointestinal infection
- **Inherited weakness of A and/or B antigen expression**
  - ✓ e.g.  $A_3$ ,  $B_x$ , cisAB...
- **Mixed field pattern due to transfusion or chimerism**


# Possible reasons for *ABO* genotyping

## 🔥 Fetal blood group determination!

- ✓ **HDN:** At least 5 documented cases of hydrops fetalis due to ABO-antibodies reported since 1988. Ethnic/geographic variation.
- ✓ **NAITP:** Samples from such a case have been referred to our lab


## 🔥 Confirmation of $A_2$ status in $A_2$ to O kidney transplant

# Major *ABO* alleles recognised in 1994




-  = translated, *A*<sup>1</sup> consensus
-  = nucleotide substitution, leading to amino acid change
-  = translated, non-*A*<sup>1</sup> consensus

# Duplex PCR-RFLP method for ABO genotyping




# Duplex PCR-RFLP method for *ABO* genotyping




3. Electrophoresis in agarose gel  
Resolution of >15 genotypes

# Identical genotyping patterns can result in completely different phenotypes







# Hybrid-proof rapid PCR detection of common and rare *ABO* alleles



# **ABO PCR-ASP low-resolution typing across intron 6**


- 🔥 **Fragment sizes: 1.3 - 1.9 kb**
- 🔥 **12 primer mixes: 3 screen for rare O and A/B subgroup alleles**
- 🔥 **Numerous genotypes based on all known alleles interpretable in <3 hours**
- 🔥 **The following ABO alleles discriminated:**  
*A<sup>1</sup>, A<sup>2</sup>, A<sup>1</sup>(C467T), A<sup>subgr</sup>, B, B<sup>subgr</sup>, cisAB, B(A), O<sup>1</sup>, O<sup>1v</sup>, O<sup>1</sup>(C467T), O<sup>1</sup>-B, O<sup>1</sup>-A<sup>2</sup>, O<sup>2</sup>, O<sup>3</sup>, O<sup>4</sup>, O<sup>5</sup>*
- 🔥 **FLEXIBILITY**, i.e. primers detecting mutations in novel alleles can be added continuously

# ABO PCR-ASP gels




Olsson et al. *Transfusion* 1998; 39:3S

# Schematic model of the JK glycoprotein



# JK Genotyping



- PCR-ASP
- Single PCR (10 uL)
- Validation:
  - 119 samples
  - 100% concordance
- Amniotic DNA OK

*Irshaid NM, Thuresson B, Olsson ML. Br J Haematol 1998;102:1010-14*



# Current Genomic Testing for Blood Group Antigens

## 🔥 Testing performed:

- ✓ Foetal DNA to predict foetal RBC phenotype
- ✓ Prediction of RBC phenotype in multi-transfused patients
- ✓ Resolution of serological discrepancies e.g. weak D, ABO subgroups
- ✓ Resolution of rare variants

## 🔥 Mostly **single/few samples** per analysis

# Can We “Type” Blood Donors by Genotyping?

## WHY?

- 🔥 Limited selection of antisera
- 🔥 Scarcity of source material
  - ✓ Few immunized donors with potent antibodies for reagent manufacture
  - ✓ Zero risk climate eliminated immunization and boosting programs
  - ✓ Monoclonal antibodies not available for all antigens

# Should We “Type” Blood Donors by Genotyping?

- 🔥 **Use of donor RBCs for in-house antibody detection and identification reagents**
- 🔥 **Quality Assurance of Reagent Test RBCs**
  - ✓ **Determination of single/double dose antigens for D, Fy<sup>a</sup>, Fy<sup>b</sup>**

# Requirements for Large Scale Genomic Typing

- 🔥 Automated DNA extraction
- 🔥 Potential for automated PCR set-up
- 🔥 Rapid, automated post-PCR analysis of numerous blood group polymorphisms
- 🔥 Closed system to prevent contamination
- 🔥 Positive sample identification and data correlation

# Potential Technology for High Throughput Genomic Typing

- Oligonucleotide Microarray
- High Performance Liquid Chromatography (HPLC)
- Matrix-Assisted Laser Desorption /Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF)
- Pyrosequencing

None of these techniques are automated *YET*

# **Blood Grouping and Genotyping**

**Improving Patient Safety and Blood  
Transfusion Compatibility**


# Technical Objectives

- 🔥 To demonstrate novel, nucleic acid based diagnostic tests to reduce the instance of alloimmunization
- 🔥 To provide an innovative approach to blood group genotyping on a large scale, which is easily extended to other alleles of clinical significance
- 🔥 To provide a platform technology for future clinical approaches to genotyping

# DNA Microarray Analysis

- 🔥 **Primarily used for looking at gene expression in normal and disease states, e.g.**
  - ✓ **Haematologic malignancies**
  - ✓ **Solid organ tumours**
- 🔥 **Increasing use in SNP analysis**
- 🔥 **Potentially automated**

# Principle of Microarray Analysis



Microscope slide spotted with specific oligonucleotides

- ◆ Multiplex PCR products are labeled with red or green fluorescent dye
- ◆ DNA is hybridised with synthetic oligonucleotide probes on slide
- ◆ Fluorescence measured by spectrophotometer
- ◆ Specific spots will fluoresce as the different DNAs bind
- ◆ Image is produced by the computer analysis program
- ◆ Comparison is made between test and control patterns

# Challenges of Using Microarray for SNP Analysis

- 🔥 Homologous genes are difficult to analyse:
  - ✓ SNPS in *RHD* may be consensus sequence in *RHCE*
  - ✓ Must be amplified in separate multiplexes
  - ✓ Experimental procedure does not allow for identity of SNPs in *cis* or *trans*
- 🔥 Data analysis is the biggest workload burden
  - ✓ Analysis files may be Gigabytes in size!

# Advantages of Microarrays

- 🔥 **Enormous potential to gather data on known alleles and to detect new mutations**
- 🔥 **Automation potential although many manual steps currently**
  - ✓ **Good platform for donor testing**
  - ✓ **Could be used for testing a wide variety of phenotypic and genotypic differences**

# Conclusions

- 🔥 **28 of 29 blood group genes have been identified**
  - ✓ Blood group polymorphisms can be explained at the genetic level
- 🔥 **Blood group genes provide insights into gene processing and rearrangement**
- 🔥 **Molecular analysis of blood group genes is clinically useful and has potential in the Blood Center**
- 🔥 **Understanding of molecular basis permits exploration of protein function**

# Some Reviews from the BloodGen Group 1997-2004

1. Storry JR, Olsson ML. Genetic basis of blood group diversity. *Brit J Haem*, 2004;759-71
2. Daniels G. Molecular blood grouping. *Vox Sang*. 2004;87 Suppl1:63-6.
3. Storry JR. Molecular basis of erythrocyte blood group antigens and applications in transfusion medicine. *Vox Sang*. 2002;83 Suppl 1:81-4.
4. Northoff, Flegel WA. Genotyping and phenotyping: the two sides of the coin. *Infusionsther Transfusionsmed* 1999;26:5
5. Avent ND. Molecular genetic methods: principles and feasibility in transfusion medicine. *Vox Sang* 1998;74:275-84
6. Avent ND. Human erythrocyte antigen expression: its molecular bases. *Brit J Biomed Sci* 1997;54:16-37